Dr. Liu’s group reported that a CML patient harboring the BCR-ABL1 mutations (T315I and E255V) achieved successful DMR by dasatinib + IFN-α [121], and combination therapies were subsequently applied in clinical trials in CML patients. The gene discussed is IFNA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.